Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PERFORM: A Phase II Study of Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas

NCT06300528 is registered in ClinicalTrials.gov with University of Utah as lead sponsor.

NCT NCT06300528
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06300528 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PERFORM: A Phase II Study of Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
Lead sponsor
University of Utah
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 3, 2025
Completion date
March 31, 2027
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mantle cell lymphoma, marginal zone lymphoma, relapsed or refractory b-cell non-hodgkin lymphoma